ITIF Report: Global Drug Price Controls Restrict Pharmaceutical Research and Development
The Information Technology and Innovation Foundation (ITIF) study reports that drug price controls in non-US Organization for Economic Cooperation and [...]
Economists Suggest That Universal Coverage Is Already Possible for the US: What Obstacles Still Stand in the Way?
The current state of health insurance in the U.S. needs to be revised, even for insured Americans who face the [...]
BridgeBio’s Experimental Results Boosts Company Shares by 65%
BridgeBio Pharma Inc's experimental drug, acoramidis, for rare heart disease, has shown significant improvement in a late-stage study, boosting its [...]
FDA Approves AstraZeneca’s Beyfortus
The Food and Drug Administration has approved an AstraZeneca-developed monoclonal antibody, Beyfortus, in an effort to protect infants and young [...]
J&J Subsidiary Sues Doctors Over Talc-Cancer Research
Johnson & Johnson's subsidiary LTL Management has filed lawsuits against four doctors who have published studies suggesting links between J&J's [...]
Revolution in Women’s Health: First Over-The-Counter Contraceptive Coming to U.S. Shelves in 2024!
Perrigo's oral contraceptive, Opill, is now the first over-the-counter birth control pill in the United States. Opill has been around [...]
Insights into the Global Real World Evidence Solutions Market 2023-2030
10 Things You Need to Know: The projection shows the market size growing from $16.3 billion in 2023 to $36.24 [...]
Unmasking Healthcare Costs: Beyond Transparency
What You Need to Know: Policymakers have shifted focus towards price transparency in healthcare to combat escalating costs; however, merely [...]
Is AI the Future of Pharma?
Here's What People Are Saying... ChatGPT is revolutionizing the pharmaceutical industry. Artificial intelligence and machine learning are expediting medication development, [...]
Price Break: Cigna Welcomes Trio of Discounted Biosimilars to Preferred Drug Roster
What You Need to Know: Cigna Group's unit, Express Scripts, is adding three biosimilar versions of AbbVie's arthritis treatment Humira [...]
Will the Medicare Price Negotiation Revamp Sufficiently Appease Pharma Companies?
The Centers for Medicare & Medicaid Services (CMS) amendments to its drug pricing negotiation program will unlikely deter past, current, [...]
Thermo Fisher to Acquire Data Firm CorEvitas for $912.5M
What You Need to Know: For $912.5 million, Thermo Fisher Scientific is set to acquire CorEvitas, a real-world data intelligence [...]
How Quality Research Initiatives are Advancing Precision Oncology and Value-Based Care
Precision medicine and value-based care are buzzwords used over the last two decades. At inception, these principles were seen [...]
Value-Based Agreements – Are We Going to See More or Less of Them?
Mike Pace, MBA, Pierre Etienne, MD, and Clifton Chow give an insightful and practical webinar on one of the most important areas in pharmaceutical value and market access.
Study Finds Inconsistent Reimbursement Assessments Across EU Markets
While some modifications in the HTA process for orphan drugs have had some positive impacts, manufacturers still face key hurdles [...]
Article: U.S. Should Scrap Specialty Drug Label
The U.S. should abandon the specialty-drug label for high-cost drugs and follow suit with other countries that categorize drugs by [...]
Massachusetts to Pay for Zolgensma on One Condition: It Must Work
Massachusetts' Medicaid program, MassHealth, has inked a conditional deal for Novartis' $2 million one-time spinal muscular atrophy (SMA) gene therapy, [...]
Price of Decades-Old Drug Skyrockets, Georgia City Sues
The price of Belcher Pharmaceuticals' Acthar gel skyrocketed after having been granted orphan status by the Food and Drug Administration, [...]
BioMarin CFO Exits Before Release of Costly Drug
BioMarin Pharmaceutical is searching for a new chief financial officer following Dan Spiegelman's exit last week, Forbes reports. The executive's [...]
What Do Value Assessments Miss? Rethinking Value Using New Health Economics Evidence.
Dr. Patti Peeples, CEO and Founder of HealthEconomics.Com, recently sat down with Dr. Anupam Jena, Scientific Advisor, Precision Xtract, to discuss his latest research that expands the definition and measurement of value of novel therapies by using new health economics evidence.
Real-world evidence and value-based contracting – swipe left or swipe right?
As biopharma makes the shift toward a personalized healthcare system, it is also transitioning towards a pipeline full of innovative, [...]
Big Ideas for Big Data Analytics in Real-World Evidence: Insights from Dr. Rich Gliklich, CEO of OM1
Dr. Patti Peeples, CEO of HealthEconomics.Com, sat down with Dr. Rich Gliklich, CEO of OM1, to discuss how big [...]
How Should Health Care Providers Measure and Market the “Value” of their Services?
John Schneider, Ph.D There was a time when we did not spend a lot of time worrying about [...]
Integration of Novel Diagnostics into Clinical Practice
By John Schneider, Ph.D Similar to drug and device markets, a critical part of the success of novel [...]